Status:
COMPLETED
Safety, Tolerability and Pharmacokinetics of NTP42:KVA4
Lead Sponsor:
ATXA Therapeutics Limited
Collaborating Sponsors:
Hammersmith Medicines Research
Conditions:
Healthy
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
A Phase I clinical trial to assess the safety, tolerability, and pharmacokinetics of NTP42:KVA4 following oral administration in a randomized, double-blind, placebo-controlled trial. The trial will in...
Eligibility Criteria
Inclusion
- A body mass index (BMI) in the range 18.0-30.0.
- Ability \& willingness to provide written consent.
Exclusion
- Clinically relevant abnormal medical history, physical findings, laboratory values at pre-trial screening.
- History of bleeding disorders, coagulation variables or abnormal blood cell count.
- History of chronic illness.
- Impaired endocrine, thyroid, hepatic, renal or respiratory function, diabetes mellitus, coronary heart disease or history of any psychotic mental illness.
- History of adverse reaction or allergy to any drug.
- Use of aspirin, other non-steroidal anti-inflammatory drugs (NSAIDs), or any other medicine that affects platelet function or coagulation, or any prescription medicine, during the 28 days before the first dose of trial medication.
- History of drug or alcohol abuse
- Smoker or use of nicotine-containing products
- Blood pressure or heart rate at screening outside normal ranges.
Key Trial Info
Start Date :
May 24 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 20 2022
Estimated Enrollment :
79 Patients enrolled
Trial Details
Trial ID
NCT04919863
Start Date
May 24 2021
End Date
January 20 2022
Last Update
February 24 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hammersmith Medicines Research
London, United Kingdom, NW10 7EW